Quality of life related to oral versus subcutaneous iron chelation: A time trade-off study

Value in Health

Volumn 10, Issue 6, 2007, Pages 451-456

  Osborne, Richard H ^a   De Abreu Lourenço, Richard ^b   Dalton, Andrew ^a   Houltram, Jennifer ^b   Dowton, David ^b   Joshua, Douglas Edgar ^c   Lindeman, Robert ^d   Ho, Phoebe Joy ^e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Pty Ltd   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e CENTENARY INSTITUTE   (Australia)

Author keywords

Administration route; Iron chelation; Quality of life; Time trade off

Indexed keywords

DEFERASIROX; DEFEROXAMINE; IRON;

ADULT; ARTICLE; AUSTRALIA; COMMUNITY CARE; CONTROLLED STUDY; FEMALE; HUMAN; IRON CHELATION; MALE; NORMAL HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE;

ADMINISTRATION, ORAL; ADULT; CHELATION THERAPY; DEFEROXAMINE; FEMALE; HUMANS; INFUSION PUMPS; INFUSIONS, PARENTERAL; IRON OVERLOAD; MALE; MIDDLE AGED; NEW SOUTH WALES; PATIENT SATISFACTION; QUALITY OF LIFE; SIDEROPHORES; TIME FACTORS;

EID: 35548973839     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00200.x     Document Type: Article

References (15)

1. Britton RS, Leicester KL, Bacon BR. Iron toxicity and chelation therapy. Int J Hematol 2002 76 : 219 28.
2. Cappellini MD, Cohen A, Piga A, et al. A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with {beta}-thalassemia. Blood 2005 107 : 3455 62.
3. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003 361 : 1597 602.
4. Basran RK, Fasson FF, Shaw D, Olivieri NF. Assessment of the relative quality of life in patients receiving subcutaneous deferoxamine and the orally active iron chelating agent. Blood 1994 84 : 261a.
5. Dolan P. Output measures and valuation in health. In : Drummond M, McGuire A, eds. Economic Evaluation in Health Care. Merging Theory with Practice. Oxford : Oxford University Press, 2001.
6. Torrance G. Utility measurement in healthcare. The things I never got to. Pharmacoeconomics 2006 24 : 1069 78.
7. Wyrwich KW, Tierney WM, Babu AN, et al. A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease. Health Services Research 2005 40 : 577 92.
8. Abetz L, Baladi J, Jones P, et al. The impact of iron overload and its treatment on quality of life: results from a literature review. Health Qual Life Outcomes 2006 4 : 1 6.
9. Johnson ES, Sullivan SD, Mozaffari E, et al. A utility assessment of oral and intravenous ganciclovir for the maintenance treatment of AIDS-related cytomegalovirus retinitis. Pharmacoeconomics 1996 10 : 623 9.
10. Stinnett A, Mittleman M, Weinstein M. C-E of dietary & pharmacologic therapy for cholesterol reduction in adults. In : Gold M, Siegel J, Russell L, et al., eds. Cost-Effectiveness in Health and Medicine. Oxford : Oxford University Press, 1996.
11. Holohan TV. Cost-effectiveness modeling of simultaneous pancreas-kidney transplantation. Int J Technol Assess Health Care 1996 12 : 416 24.
12. Revicki DA. Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidence. Curr Opin Invest Drugs 2001 2 : 110 17.
13. Nease RF Jr, Kneeland T, O'Connor GT, et al. Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team. JAMA 1995 273 : 1185 90.
14. Froberg DG, Kane RL. Methodology for measuring health-state preferences - II: scaling methods. J Clin Epidemiol 1989 42 : 459 71.
15. Salkeld G, Cameron ID, Cumming RG, et al. Quality of life related to fear of falling and hip fracture in older women: a time trade off study. BMJ 2000 320 : 341 6.